Chiron Real Estate Inc. (XRN)
NYSE:XRN
Want to see XRN full AI Analyst Report?
Top Page
Chiron Real Estate ate
(NYSE:XRN)
Select Model
Select Model
Rating:49Neutral
Price Target:
$34.00
▼(-4.23% Downside)
Action:Reiterated
Date:05/21/26
The score is primarily held back by weaker financial performance (2025 net loss, higher leverage, and recurring negative free cash flow). Earnings-call factors are moderately supportive due to improving leverage and a strategic investor backing a portfolio transition, but reduced guidance visibility and a dividend cut offset that. Technical signals are neutral-to-mixed, while valuation is pressured by a very high P/E despite a strong dividend yield.
Positive Factors
Underlying cash flow growth (FFO & NOI)
Consistent same-store cash NOI growth and positive FFO trends indicate durable portfolio cash generation that supports coverage of interest and distributions. Over a multi-quarter horizon, steady NOI/FFO growth underpins reinvestment capacity and improves the quality of reported cash earnings versus transitory items.
Negative Factors
Elevated leverage and shrinking equity
Rising leverage and declining equity reduce the balance sheet cushion against operational shocks and increase sensitivity to earnings volatility. Even with some deleveraging progress, higher net leverage constrains strategic flexibility, raises refinancing and covenant risk, and magnifies the impact of any future cash flow weakness.
Read all positive and negative factors
Positive Factors
Negative Factors
Underlying cash flow growth (FFO & NOI)
Consistent same-store cash NOI growth and positive FFO trends indicate durable portfolio cash generation that supports coverage of interest and distributions. Over a multi-quarter horizon, steady NOI/FFO growth underpins reinvestment capacity and improves the quality of reported cash earnings versus transitory items.
Read all positive factors
Chiron Real Estate ate Key Performance Indicators (KPIs)
Chiron Real Estate ate (XRN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$524.80M
Dividend Yield10.01%
Average Volume (3M)156.25K
Price to Earnings (P/E)63.5
Beta (1Y)0.62
Revenue Growth6.08%
EPS Growth-815.66%
CountryUS
Employees26
SectorReal Estate
Sector Strength53
IndustryREIT - Industrial
Share Statistics
EPS (TTM)-1.12
Shares Outstanding13,234,830
10 Day Avg. Volume309,480
30 Day Avg. Volume156,252
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.92
Price to Sales (P/S)2.90
P/FCF Ratio-57.89
Enterprise Value/Market Cap2.23
Enterprise Value/Revenue7.38
Enterprise Value/Gross Profit298.34
Enterprise Value/Ebitda13.05
Forecast
1Y Price Target
$40.60Price Target Upside14.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.13
Revenue Forecast (FY)$159.74M
Chiron Real Estate ate Business Overview & Revenue Model
Company Description
Global Medical REIT, Inc. engages in the acquisition of purpose-built healthcare facilities and the leasing of those properties to healthcare systems and physician groups. The company was founded on March 18, 2011 and is headquartered in Bethesda,...
How the Company Makes Money
Global Medical REIT primarily makes money by acquiring healthcare real estate and leasing those properties to tenants under lease agreements. Its core revenue stream is rental income (base rent) paid by healthcare providers and operators that occu...
Chiron Real Estate ate Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 05, 2026
Earnings Call Sentiment Positive
The call describes a strategic, well-capitalized repositioning toward senior housing with a $100M strategic investor, positive quarterly operating metrics (FFO and same-store NOI growth) and improving leverage. These positives are balanced against short-term visibility challenges: a dividend reduction, withdrawal of 2026 guidance, a timing/funding gap to fully fund announced investments, and lease-up/stabilization risk for newly acquired assets. Overall, management framed the moves as deliberate steps to create long-term value through capital recycling and retained cash flow.Positive Updates
Strategic Repositioning into Senior Housing (SHOP)
Following recent transactions, Chiron will have over 25% of asset value in senior housing operating properties (SHOP), marking a meaningful portfolio shift toward senior housing and a focused healthcare-related platform aimed at long-term earnings growth and portfolio quality improvement.
Negative Updates
Distribution Cut Impacts Current Income
Monthly distribution reduced to an annual run rate of $1.92 per share ($0.16/month) beginning in July, a decision that reduces current cash returns to shareholders (management frames this as a capital allocation choice to retain $15 million/year).
Read all updates
Q1-2026 Updates
Positive
Negative
Strategic Repositioning into Senior Housing (SHOP)
Following recent transactions, Chiron will have over 25% of asset value in senior housing operating properties (SHOP), marking a meaningful portfolio shift toward senior housing and a focused healthcare-related platform aimed at long-term earnings growth and portfolio quality improvement.
Read all positive updates
Company Guidance
Management withdrew 2026 earnings guidance to focus on the portfolio transition but reiterated full‑year cash and noncash G&A and FAD capex expectations, and they cut the monthly distribution to an annual run rate of $1.92 per share ($0.16/month) starting in July to retain roughly $15 million of capital annually; Q1 operating metrics were NAREIT FFO/share/unit $0.97, core FFO $1.11, net debt/adjusted EBITDA 6.6x (down 0.4x YoY) and same‑store cash NOI +3.2% YoY. Strategic financing and portfolio metrics highlighted a $100 million Maewyn investment (with Charles Fitzgerald joining the Board and >20% ownership on a fully diluted as‑converted basis), approximately $300 million of capital sources to fund roughly $425 million of identified investments (including a $176 million Pinnacle close expected Aug–Nov), about $200 million of pending asset sales under LOI plus ~$125 million of targeted future dispositions, an implied share‑price cap rate of 9% versus recent comps at 7.3%–7.9% (100–150 bps arbitrage), underwritten stabilized yields >7% (untrended rents) with potential for double‑digit unlevered returns, and a long‑term earnings growth target of ~6% with portfolio stabilization expected around 2027–2028 (second half of ’28).Chiron Real Estate ate Financial Statement Overview
Summary
Income Statement
53
Neutral
Balance Sheet
48
Neutral
Cash Flow
41
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 158.29M | 161.03M | 138.41M | 140.93M | 137.17M | 115.80M |
| Gross Profit | 3.92M | 10.32M | 109.16M | 112.85M | 111.98M | 100.32M |
| EBITDA | 89.53M | 96.73M | 91.47M | 111.64M | 102.89M | 85.35M |
| Net Income | -7.67M | -5.84M | 6.63M | 20.61M | 19.14M | 17.62M |
Balance Sheet | ||||||
| Total Assets | 1.24B | 1.24B | 1.26B | 1.27B | 1.39B | 1.26B |
| Cash, Cash Equivalents and Short-Term Investments | 8.18M | 12.45M | 6.82M | 1.28M | 4.02M | 7.21M |
| Total Debt | 681.12M | 663.74M | 653.59M | 624.19M | 704.65M | 579.86M |
| Total Liabilities | 717.37M | 712.40M | 700.57M | 661.89M | 744.20M | 625.91M |
| Stockholders Equity | 500.21M | 509.77M | 534.13M | 583.58M | 632.98M | 622.78M |
Cash Flow | ||||||
| Free Cash Flow | 57.98M | -8.08M | -25.07M | 58.39M | -79.66M | -132.69M |
| Operating Cash Flow | 61.34M | 73.61M | 70.05M | 68.44M | 76.54M | 68.97M |
| Investing Cash Flow | -33.18M | -60.40M | -45.94M | 67.62M | -137.25M | -194.66M |
| Financing Cash Flow | -23.86M | -10.26M | -21.89M | -143.79M | 62.41M | 127.70M |
Chiron Real Estate ate Technical Analysis
Positive
35.50
Price Trends
34.12
Positive
34.44
Positive
33.30
Positive
Market Momentum
0.25
Negative
64.61
Neutral
90.32
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XRN, the sentiment is Positive. The current price of 35.5 is above the 20-day moving average (MA) of 34.62, above the 50-day MA of 34.12, and above the 200-day MA of 33.30, indicating a bullish trend. The MACD of 0.25 indicates Negative momentum. The RSI at 64.61 is Neutral, neither overbought nor oversold. The STOCH value of 90.32 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XRN.
Chiron Real Estate ate Risk Analysis
Chiron Real Estate ate disclosed 63 risk factors in its most recent earnings report. Chiron Real Estate ate reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Chiron Real Estate ate Peers Comparison
UnderperformOutperform
Sector (65)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $1.67B | 26.06 | 2.81% | 6.98% | 9.37% | 6.95% | |
66 Neutral | $176.96M | 2.38 | 167.61% | 4.62% | 24.57% | 7.81% | |
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
62 Neutral | $501.15M | 42.08 | 1.41% | 12.08% | 5.24% | ― | |
61 Neutral | $2.21B | -9.23 | -18.75% | 0.80% | 0.39% | -8.95% | |
56 Neutral | $580.42M | 27.89 | 11.44% | 7.51% | 0.77% | -4.74% | |
49 Neutral | $524.80M | 63.49 | -1.54% | 10.01% | 6.08% | -815.66% |
* Real Estate Sector Average
XRN
Chiron Real Estate ate
37.45
9.29
32.99%
DHC
Diversified Healthcare Trust
8.90
5.92
198.26%
CHCT
Community Healthcare
17.72
3.52
24.79%
UHT
Universal Health Realty Income
42.12
6.87
19.50%
STRW
Strawberry Fields REIT Inc
13.27
3.87
41.22%
SILA
Sila Realty Trust, Inc.
30.25
7.36
32.16%
Chiron Real Estate ate Corporate Events
Business Operations and StrategyExecutive/Board ChangesDividendsShareholder Meetings
Chiron Real Estate Expands Board, Strengthens Governance Oversight
Positive
May 20, 2026
On May 20, 2026, Chiron Real Estate Inc. expanded its board from six to seven members and appointed veteran real estate investor Charles Fitzgerald as an independent director, with roles on the Compensation and Nominating and Corporate Governance ...
Business Operations and StrategyPrivate Placements and Financing
Chiron Real Estate Raises Capital via Preferred Stock Placement
Neutral
May 8, 2026
On May 6, 2026, Chiron Real Estate Inc. agreed to raise up to $100 million through a private placement of 1,000,000 shares of 6.00% Series C Convertible Perpetual Preferred Stock at $100 per share, with proceeds earmarked for general corporate and...
Business Operations and StrategyDividendsFinancial DisclosuresM&A TransactionsPrivate Placements and Financing
Chiron Real Estate Resets Dividend to Fund Growth
Neutral
May 6, 2026
On May 1 and May 6, 2026, Chiron Real Estate Inc. agreed to acquire three newly built luxury senior housing communities in Alexandria, Virginia and North Bethesda, Maryland for a combined roughly $425 million, all to be operated as seniors housing...
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Global Medical REIT Expands Equity and Preferred Stock Programs
Positive
Mar 13, 2026
On March 11, 2026, Chiron Real Estate Inc. filed supplementary charter documents in Maryland to classify an additional 3,000,000 shares as 8.00% Series B Cumulative Redeemable Preferred Stock, lifting its total authorization to 5,300,000 preferred...
Business Operations and StrategyPrivate Placements and Financing
Global Medical REIT Establishes New Uncommitted Senior Note Facility
Positive
Mar 3, 2026
On March 2, 2026, Chiron Real Estate LP and its guarantor Chiron Real Estate Inc. entered into a Master Note and Guaranty Agreement with NYL Investors LLC and New York Life affiliates, creating an uncommitted senior note facility of up to $150 mil...
Business Operations and StrategyStock BuybackDelistings and Listing ChangesDividendsFinancial DisclosuresLegal ProceedingsPrivate Placements and Financing
Chiron Unveils Rebrand, Dividend Shift and 2026 Strategy
Positive
Feb 25, 2026
Chiron Real Estate Inc., previously known as Global Medical REIT Inc., has completed a corporate rebrand effective February 23, 2026, including a legal name change for both the company and its operating partnership, new NYSE trading symbols, and t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.